Junyan Li1, Hao Lu, Feng Tao, Hua Zhou, Guoyying Feng, Lin He, Ligang Zhou. 1. Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Department of Endocrinology, Diabetes Research Institute, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, PR China. lijunyan323@gmail.com
Abstract
INTRODUCTION: Previous case-control studies have suggested that the -1562C/T and R279Q polymorphisms of the matrix metalloproteinase 9 gene (MMP9) are associated with coronary heart disease (CHD). However, other studies do not confirm these relationships. The objective is to assess these relationships using meta-analysis. METHODS: Databases, including PubMed and ScienceDirect, were searched to access the genetic association studies. Then data were extracted. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated. Moreover, subgroup and sensitive analysis were performed. RESULTS: The meta-analysis of the -1562C/T polymorphism included 12 studies with 8,336 cases and 3,984 controls. The -1562T allele was significantly associated with CHD (OR 1.25, 95% CI 1.08-1.45, p = 0.004). There was heterogeneity among the 12 studies (I2 = 61%, p = 0.003). The overall results were consistent and were not changed substantially by the removal of any data set. The meta-analysis of the R279Q polymorphism, including 6 studies with 6,983 cases and 3,282 controls, showed that the R279Q polymorphism was not associated with CHD (p = 0.16). CONCLUSIONS: The synthesis of available evidence supports the fact that the MMP9 -1562C/T polymorphism is a risk factor for CHD.
INTRODUCTION: Previous case-control studies have suggested that the -1562C/T and R279Q polymorphisms of the matrix metalloproteinase 9 gene (MMP9) are associated with coronary heart disease (CHD). However, other studies do not confirm these relationships. The objective is to assess these relationships using meta-analysis. METHODS: Databases, including PubMed and ScienceDirect, were searched to access the genetic association studies. Then data were extracted. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated. Moreover, subgroup and sensitive analysis were performed. RESULTS: The meta-analysis of the -1562C/T polymorphism included 12 studies with 8,336 cases and 3,984 controls. The -1562T allele was significantly associated with CHD (OR 1.25, 95% CI 1.08-1.45, p = 0.004). There was heterogeneity among the 12 studies (I2 = 61%, p = 0.003). The overall results were consistent and were not changed substantially by the removal of any data set. The meta-analysis of the R279Q polymorphism, including 6 studies with 6,983 cases and 3,282 controls, showed that the R279Q polymorphism was not associated with CHD (p = 0.16). CONCLUSIONS: The synthesis of available evidence supports the fact that the MMP9-1562C/T polymorphism is a risk factor for CHD.